US › Healthcare

Adagene Inc (ADAG)

US · Healthcare · Biotechnology

$3.64+0.28%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$7.7M

Net profit

$-4.1M

Profit YoY

+51.3%

EPS

$0.00

EPS estimate

$-0.21

Net margin

-53.9%

EPS came in at 0.00 against a street estimate of -0.21 — a beat of 100.0%.

Key statistics

Market cap

$247.8M

Forward P/E

0.0

P/B

7.01

Book value

$0.75

EPS (TTM)

$-0.38

52-week high

$4.85

52-week low

$1.30

50-day MA

$3.75

200-day MA

$2.97

Beta

0.58

Analyst view

Analysts rate Adagene Inc a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $10.74.

Shareholding

Insiders

21.61%

Institutions

12.73%

Largest institutional holders

Fund	Stake
HSG Holding Ltd	2.03%
Exome Asset Management LLC	1.12%
Ameriprise Financial Inc	0.92%
Mill Creek Capital Advisors LLC	0.30%
Morgan Stanley - Brokerage Accounts	0.10%
Amvescap Plc.	0.07%
SmartHarvest Portfolios, LLC	0.06%
Kamunting Street Cap Management, L.p.	0.06%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Adagene Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.